Hormonal
Tirzepatide administered once weekly produces significant weight loss (mean difference -16.32% body weight) and improves cardiometabolic markers (BMI, waist circumference, lipids, blood pressure) in patients with overweight or obesity without diabetes mellitus, though it carries a significantly elevated risk of gastrointestinal side effects.
For individuals with overweight or obesity without diabetes, tirzepatide is a highly effective pharmacological intervention for weight loss, producing greater reductions than GLP-1 RAs like semaglutide. It also improves blood pressure, lipids, and glycemic control. However, patients must be prepared for a high likelihood of gastrointestinal side effects (nausea, vomiting, diarrhea), which can lead to discontinuation. The overall risk of serious adverse events is not significantly higher than placebo, but the burden of GI symptoms is a key consideration for adherence.
Our meta-analysis revealed significant improvements in various weight-related parameters with tirzepatide. Compared with placebo, once-weekly tirzepatide led to a substantial decrease in the percentage change in body weight, with an MD of −16.32% and a 95% CI of −18.35 to −14.29 (p < 0.0001)... Tirzepatide demonstrated favorable effects on the lipid panel... GI side effects were a major limiting factor across most studies... nausea (relative risk [RR] 3.11; 2.74–3.54), vomiting (RR 5.94; 4.50–7.85), diarrhea (RR 2.92; 2.53–3.37), and constipation (RR 2.85; 2.38–3.42).
Why this rating
Based on a systematic review and meta-analysis of six randomized controlled trials (RCTs).
Source
Efficacy and Safety of Tirzepatide on Weight Loss in Patients Without Diabetes Mellitus: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
Sharath Kommu et al. · Obesity Reviews · 2025
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →